[@PeterAttiaMD] 416 ‒ The science of mitochondria: their role in health, aging, disease, and much more
Link: https://youtu.be/nYrLMyUP4S0
Duration: 138 min
Transcript: Download plain text
Short Summary
In this Peter Attia interview, guest Nav — a researcher whose lab studies mitochondria as signaling organelles, working on T-cell memory, ferroptosis, NAD and complex I pharmacology, and mitochondrial DNA/RNA release — digs into what mitochondria actually do beyond making ATP. He argues mitochondrial "boosters" and antioxidant supplements mostly miss the point, that mitochondrial dysfunction may not be a cause of aging, and that metformin fails in cancer trials mainly because tumors cannot take the drug up. The episode also covers VO2 max and lactate-threshold testing as the only practical mitochondrial readouts, a proposal to redesign metformin trials around mechanism, and a call for a government-backed "metabolism moonshot."
Key Quotes
- "So mitochondria do two things. They make ATP and they can make the building blocks, the metabolites that are the building blocks for new lipids, new nucleotides like DNA, RNA, right? Amino acids for for the building blocks of the protein. And that's kind of settled law." (00:02:56)
- "Yeah. So it's not it's not the glib obvious first and secondord deficiency that probably gets us into trouble. It's one of these fourth order terms that is much more nuanced at a cellular level." (00:53:55)
- "Today we know that many cancers that make a lot of lactate don't do it because electron transport or injury to respiration. In fact 95 98% of cancers have a very intact electron transport chain TCA cycle." (01:42:01)
- "Metformin typically lowers the glucose levels. If NDI1 is there, it's largely refractory. Arguing that complex one is the target." (01:02:38)
- "the plasma membrane transporter if you lose it laughs at metformin it doesn't care." (01:15:20)
Detailed Summary
Mitochondria: From Buzzword to Biology
Framing the episode: what mitochondria actually do
Peter Attia and guest Nav begin with basic mitochondrial biology rather than assuming that “mitochondrial health” is a meaningful target. The conversation develops a working view of mitochondria as signaling organelles whose roles extend far beyond ATP production.
- “Mitochondrial health,” “mitochondrial dysfunction,” and “mitochondrial boosters” have become major social-media buzzwords, with mitochondria ranked among the top ten recurring health terms.
- Nav runs a laboratory focused on mitochondria as signaling organelles, with projects involving T-cell memory, ferroptosis, NAD, complex I pharmacology, and mitochondrial DNA/RNA release.
- A second major voice in the episode is a biochemist whose doctoral work concerned cytochrome oxidase kinetics, who studies the yeast mitochondrial respiratory chain, and who holds a Michael J. Fox Foundation grant for NDI1 gene therapy.
- The conversation repeatedly separates established mitochondrial physiology from products marketed on the basis of vague “mitochondrial support,” asking whether an intervention reaches the right tissue, hits a meaningful target, and improves outcomes in humans.
- The resulting position is skeptical of broad antioxidant, NAD-boosting, and mitochondrial-booster claims, while identifying VO2 max, lactate-threshold testing, and metformin use with B12 supplementation as comparatively concrete takeaways.
The hierarchy of mitochondrial functions
The discussion distinguishes mitochondria’ two classical roles from signaling functions discovered over the last several decades. Nav’s hierarchy begins with ATP and anabolic capacity, but places signaling at the center of the episode’s more consequential biological questions.
- The first classical function is ATP production through the electron transport chain, which creates a protonmotive force that functions essentially as a membrane voltage.
- The second is the supply of metabolic building blocks through the TCA or Krebs cycle, including precursors for lipids, DNA, RNA, and amino acids.
- Red blood cells are the only body cells without mitochondria, hepatocytes contain abundant mitochondria, and a single neuron can contain thousands, reflecting differences in energetic and anabolic demand.
- Nav’s hierarchy adds a third category—signaling—comprising H2O2, protein acetylation and acylation, and the release of mitochondrial genetic material, followed by cytochrome C release as a fourth function associated with cell death.
- Mitochondria-derived acetyl-CoA drives histone acetylation and therefore influences whether chromatin is open or closed, independently of how much ATP the organelle produces.
- Mitochondrial signals also feed into pathways such as mTOR, through which mitochondria help determine metabolic states and cell-fate decisions.
- Zhao Dong Wang’s mid-1990s work established cytochrome C release as a dominant mammalian apoptosis signal, with cytochrome C activating caspases and triggering programmed cell death.
NAD, complex I, and the logic behind NAD precursors
The conversation uses NAD metabolism to connect basic biochemistry with the popularity of NR and NMN supplements. It also explains why simply adding more NAD may not address the underlying biology.
- Pyruvate entering mitochondria is converted to acetyl-CoA in a reaction that converts NAD to NADH; NADH then donates electrons at complex I, regenerating NAD and sustaining TCA-cycle activity.
- The idea behind NAD precursors is often that complex I is not working well and that additional NAD could compensate for the deficit, including in conditions such as Parkinson’s disease.
- Whether complex I becomes sufficiently impaired during ordinary aging, however, is treated as unresolved and is central to skepticism about NAD supplementation.
- One analogy depicts NADH carrying electrons into the respiratory chain as water entering a tank: electron leak changes with how “full” the oxygen acceptor system is, and a fuller tank can alter the pressure driving that leak.
- The discussion later uses metformin as a pharmacological probe of this pathway, because inhibiting complex I can shift the NADH-to-NAD balance, increase mitochondrial NADH, and reduce NAD in some tissues—the opposite of what NR or NMN is commonly intended to do.
Hydrogen peroxide: useful signal, reactive precursor, and potential toxin
Hydrogen peroxide occupies a central position in the discussion because it can transmit cellular information, participate in toxic chemistry, and connect mitochondrial biology to ferroptosis. The speakers reject both the idea that it is harmless and the older belief that age-related mitochondrial degeneration simply produces poisonous amounts.
- The electron transport chain leaks electrons, converting oxygen first to superoxide and then, through enzymes such as superoxide dismutase, to hydrogen peroxide.
- The oldest mitochondrial theory of aging proposed that progressive mitochondrial degeneration generated copious H2O2 that damaged muscle and neurons.
- Asked whether the H2O2 fraction rises across the decades from age 10 to 60 in otherwise healthy people, the answer is no: toxic concentrations are not reached because antioxidant capacity remains abundant.
- Catalase and peroxiredoxins degrade H2O2 to water, and H2O2 is comparatively less reactive than superoxide.
- H2O2 oxidizes cysteines on selected proteins as part of a signaling mechanism, meaning that eliminating it indiscriminately could interfere with normal cellular communication.
- In the presence of iron, H2O2 undergoes the Fenton reaction to form the highly reactive, short-lived hydroxyl radical.
- Hydroxyl radicals attack polyunsaturated fatty acids and initiate lipid peroxidation, creating the chain reaction now called ferroptosis, a form of cell death discovered roughly 12 years before the interview.
- Selenium is required for GPX4, which removes lipid peroxides, while vitamin E also detoxifies lipid peroxides.
- Selenium-poor regions include northern New Zealand, Sweden, and Finland, whereas the conventional US diet is relatively selenium-rich; this makes supplementation more plausible in deficient populations than in well-nourished ones.
- Vitamin C is discussed primarily as a cofactor rather than a general antioxidant: approximately 75 alpha-ketoglutarate dioxygenases require it to recycle Fe²⁺ and remain functional.
- DNA demethylases, histone demethylases, and collagen prolyl hydroxylase are among those enzymes, and two oranges a day were described as sufficient to meet the stated vitamin C requirement.
- The collagen connection also explains why topical vitamin C can preserve collagen: it supports prolyl hydroxylase activity rather than simply neutralizing oxidants on the skin.
Why antioxidant supplements often disappoint
The antioxidant discussion produces one of the episode’s clearest practical conclusions: people with adequate nutrition already possess substantial antioxidant systems, and those systems may be suppressing reactions that cells need in order to signal. This also explains why a supplement can be ineffective in general while remaining biologically important in a specific deficiency.
- Most people following an adequate diet already have enough antioxidant capacity, so additional supplementation adds little, with selenium-poor populations representing a possible exception.
- Large antioxidant doses may also remove reactive oxygen species that are functioning as signals rather than merely damaging the cell.
- Antioxidant trials in sepsis have failed and, in some cases, worsened outcomes.
- A laboratory example makes the signaling problem concrete: genetically reducing mitochondrial H2O2 production still allows a T cell to proliferate after encountering a pathogen, but the cell fails to form memory T cells.
- The result is a trade-off rather than a simple benefit: enough antioxidant capacity can prevent oxidative injury, but too much can impair immune differentiation and memory.
Mitochondrial DNA and RNA as immune signals
The release of mitochondrial nucleic acid provides a possible bridge between mitochondrial biology, inflammation, and aging. The pathway is biologically plausible and experimentally supported, but its release mechanism remains largely unresolved.
- Eukaryotes arose from symbiosis between an archaeon and an alpha-proteobacterium before oxygen existed, so mitochondrial DNA and RNA retain bacterial-like features that cellular sensors can treat as foreign.
- Released mitochondrial nucleic acid is sensed through cGAS/STING and MAVS pathways, leading to type I interferon responses that coordinate immune activity, including interferon production and T- and B-cell responses.
- Pox-virus experiments conducted with a Northwestern colleague showed mitochondrial DNA release activating precisely this interferon response.
- How the nucleic acid leaves mitochondria remains a “black box”; proposed routes include defective mitophagy and normal mitochondrial fission and fusion, whereas alpha-ketoglutarate is known to have dedicated transporters.
- The central unresolved question is whether release requires destruction of the mitochondrion, making it a binary event, or can occur from a leaky but still-intact organelle.
- One hypothesis is that small quantities of mitochondrial RNA and DNA leak slowly over 20–30 years, driving chronic inflammation and autoimmunity without materially impairing DNA, alpha-ketoglutarate, or H2O2 signaling.
- That hypothesis is difficult to test directly because the release mechanism itself is unknown; the speakers also acknowledge that they do not know why the thymus does not fully account for exposure to mitochondrial antigens.
- If a dedicated transporter were identified, it might become possible to manipulate the pathway deliberately rather than relying on indirect correlations with inflammation.
Living without mitochondria: enough energy to survive, but not necessarily function
Peter revises an earlier, more absolute view of ATP disruption during the conversation. Cells can often survive through glycolysis, but survival does not guarantee normal specialization, signaling, or long-term organ function.
- Cells with electron transport chain components knocked out can survive for months on glycolysis while activating AMPK and reducing mTOR signaling.
- In a Northwestern experiment, mice whose hearts could pump on glycolysis for months developed signaling-driven hypertrophy; the enlarged heart eventually stopped contracting, and the animals died.
- With rotenone, a complex I inhibitor associated with Parkinson’s disease, mouse dopaminergic neurons survive on glycolysis for about three months but stop producing dopamine before beginning to die.
- These examples support the distinction between enough energy to remain alive and enough energy to perform specialized functions.
- Cyanide and carbon monoxide bind cytochrome c oxidase, yet acute cyanide poisoning can kill in seconds while genetic disruption permits prolonged survival, a discrepancy that remains unexplained.
How mitochondrial function can actually be measured
The episode is unusually dismissive of noninvasive “mitochondrial function” tests because no validated proxy can reproduce what a tissue biopsy or exercise physiology can show. Practical measurements therefore focus on reserve capacity and the point at which ATP demand begins to force glycolysis.
- No reproducible noninvasive test of mitochondrial function is available; the most direct approach is a muscle biopsy analyzed through metabolomics and measurements on isolated mitochondria.
- Metabolomics provides a snapshot of TCA-cycle intermediates, while isolated mitochondria can be fed carbohydrates, fatty acids, pyruvate, or ADP to assess maximal respiratory and ATP-producing capacity.
- Function 1, maximal oxygen consumption, is analogous to a car’s top speed, while Function 2, the capacity to make ATP, is analogous to fuel economy.
- Human mitochondrial genetics suggest that roughly 70% of mitochondrial protein function can be lost before impairment appears in nearly every tissue, leaving only 20–30% functional and indicating substantial reserve capacity.
- The Aston Martin analogy emphasizes that extraordinary top speed does not matter in ordinary use: the 1964 Goldfinger car reaches about 140 mph, the latest No Time To Die car about 217 mph, and Chicago’s 50 mph limit is not the rate-limiting constraint.
- Beta-hydroxybutyrate, which can serve as an NADH/NAD surrogate, is unusually elevated in some patients with mitochondrial mutations and may act as a “canary in the coal mine.”
- The speakers ’ preferred practical test is an incremental bike or treadmill test that measures work in watts or METs while keeping lactate below 2 mmol/L; once lactate rises, the subject is increasingly shunting through glycolysis.
- This test connects whole-body exercise performance to the mitochondrial capacity that can be expressed before anaerobic metabolism becomes necessary.
VO2 max, lactate threshold, and the limits of the athlete analogy
A comparison with Tadej Pogačar becomes an extended argument about what aerobic capacity actually measures. Peter and Nav disagree over how much of the limit belongs to mitochondria versus oxygen delivery, while their lactate-threshold observations narrow the dispute.
- A recent medical-journal article predicts that Tadej Pogačar will have the highest VO2 max of any professional cyclist and will sustain approximately 7 watts per kilogram longer than any other cyclist.
- In a hypothetical head-to-head ergometer test, Peter’s lactate would begin rising at roughly 230 watts, while Pogačar would reach approximately 350 watts.
- Nav argues that mitochondrial efficiency is only one determinant of aerobic capacity because the cardiovascular system must also deliver sufficient oxygen to mitochondria.
- Peter responds that at the lactate threshold both men are operating at only about 60–70% of VO2 max, meaning oxygen delivery is not yet the limiting factor at that point.
- Nav divides aerobic performance into three inputs: cardiac output through heart rate, stroke volume, and contractility; blood flow and oxygen delivery, including hemoglobin; and the efficiency with which mitochondria use oxygen rather than relying on phosphocreatine or glycolysis.
- High cardiac output provides little benefit if hemoglobin or oxygen delivery is inadequate, while strong mitochondria cannot compensate for inadequate substrate delivery.
- Peter says he runs the lactate-threshold test on all of his patients and has never observed LT1, approximately the start of zone two, outside the 60–70% VO2-max region.
- He consequently describes the protocol as a practical “poor man’s test” of mitochondrial function, while Nav continues to distinguish mitochondrial efficiency from the cardiovascular contribution.
- VO2 max declines by approximately 10% per decade, with cited functional thresholds around 28–30 ml/kg for quality of life, about 20 for some people, and roughly 15–16 ml/kg for maintaining independent living.
- The practical recommendation is to maximize VO2 max while it remains available, preserving optionality for the inevitable decline; Peter also cautions that some age-related loss may be neuromuscular rather than mitochondrial.
- A longitudinal study of unfit, untrained, non-exercising people found VO2 max more limited by peripheral oxygen transfer, but the speakers state that this finding does not apply to people who train.
Does mitochondrial dysfunction cause aging?
Nav openly questions whether mitochondrial dysfunction is necessary for aging and identifies his professional conflict of interest in defending mitochondrial theories. The argument turns on a basic distinction between showing that a defect can produce an aging phenotype and showing that the defect is required for normal aging.
- Hallmark-of-aging experiments are described as sufficiency tests: perturbing mitochondria or lysosomes can create an aging-like phenotype, but that does not establish necessity.
- Mouse models carrying nuclear DNA mutations at levels found in a normally aged mouse do reproduce multiple hallmarks of aging.
- Mitochondrial DNA mutations must be introduced at roughly ten times the normal rate before degeneration appears, and even then outcomes such as hair loss do not fully resemble normal aging.
- A mouse engineered early in life to carry the normal amount of mitochondrial mutation showed no corresponding phenotype.
- Knocking out mitochondrial function in microglia, a cell type important in inflammation and brain function, at one year of age did not make the mouse look aged.
- Other age-related mechanisms—including protein degradation, membrane permeability, and translational failure—remain plausible sources of mitochondrial dysfunction.
- Nav argues that the likely aging-related problem is not ATP capacity, which he thinks is probably retained, or a general shortage of TCA metabolites, which he thinks is unlikely.
- Instead, he proposes miscommunication among mitochondria, particularly altered H2O2 signaling, as a higher-order effect that hallmarks experiments may miss.
- Genetically reducing H2O2 production impairs immune-cell differentiation in mice, although it remains unknown whether the same signaling defect develops during ordinary human aging.
- Alpha-ketoglutarate levels decline with age, and Nav is testing whether reduced availability contributes to DNA methylation problems and impaired differentiation.
Metformin’s epidemiological story and its weaknesses
The discussion does not dismiss metformin, but it treats the original geroprotective case as less secure than the early enthusiasm suggested. Epidemiological uncertainty is then followed by a more detailed account of where oral metformin goes and how cells gain access to it.
- The Banister paper that ignited interest in metformin as a geroprotective agent reported that non-diabetic people not taking metformin had worse cancer outcomes than diabetic people taking metformin.
- Approximately eight years later, the Keys paper repeated the analysis with and without the statistical method used in the original study and did not reproduce the finding.
- Nav considers the later analysis more convincing, describing metformin’s epidemiological case as shakier without concluding that the drug has no value.
- A phase 3 metformin trial in breast cancer failed, while a prostate cancer trial showed some signal.
- C11 PET imaging shows that orally administered metformin is absorbed first in the gut, with the intestines and colon becoming visibly active.
- The drug then travels through the portal vein to the liver, reaches the kidney, and is excreted within a couple of hours.
- Appreciable oral metformin concentrations are not maintained in the brain, heart, or muscle.
- Reported concentrations fall from as much as about 1 mM in the gut to roughly 50–100 µM at its maximum in the liver and around 10 µM in blood, an approximately 20-fold decline from gut to liver.
- Entry into and exit from cells depends on organic cation transporters, including OCT1, OCT2, and OCT3; uptake has been observed in macrophages and certain T-cell populations.
Complex I and NDI1 establish metformin’s principal target
NDI1 serves as the central experimental tool for testing whether complex I is necessary for metformin’s effects. The resulting mouse and imaging experiments provide substantially stronger mechanistic evidence than the original epidemiological association.
- Metformin’s ability to inhibit complex I was recognized by biochemists about 25 years ago.
- Mammalian complex I is the largest respiratory-chain complex, with 45 subunits encoded by both nuclear and mitochondrial DNA.
- In some tissues, metformin lowers mitochondrial NAD and raises mitochondrial NADH, which is the opposite of the change sought by most NAD-boosting supplements.
- NDI1 is a single yeast protein that functions as a homodimer, transfers electrons from NADH to the rest of the respiratory chain, and bypasses complex I without reproducing all of its functions.
- In mice with complex I knocked out in dopaminergic neurons, introducing NDI1 restored neuron health; the neurons were described as functioning normally again.
- A mouse expressing both complex I and NDI1 was largely refractory to metformin’s usual glucose-lowering effect, supporting complex I inhibition as the causal mechanism.
- Zach engineered mice with NDI1 expressed only in the gut, and FDG PET imaging showed that metformin-induced gut glucose uptake was completely absent in those animals.
- In normal mice, metformin increases gut glucose uptake because inhibition of the electron transport chain forces cells to take up glucose and run glycolysis toward lactate; this is why cancer patients are commonly instructed to stop metformin before FDG PET.
- Cryo-EM work mapped metformin’s binding sites within complex I, including subunit a, and found no inhibition of the other respiratory complexes, contradicting the smaller body of claims that complex IV is also a target.
- It remains unknown how metformin crosses from the cytoplasm into the mitochondrial matrix; cellular entry through OCT transporters is established, but matrix entry is not.
Citrulline, exercise adaptation, B12, and other metformin consequences
Metformin’s complex I inhibition produces several downstream effects beyond glucose lowering. The conversation identifies both potentially beneficial mechanisms and reasons for caution, especially in people who exercise or take the drug long term.
- GDF-15, an appetite-suppressing hormone, rises with metformin, and gut-derived GLP-1, lactate, and alanine changes are abrogated when complex I is bypassed in the gut-specific NDI1 mice.
- The liver contribution to these metabolic effects has not been tested in the same bypass model.
- Citrulline is the metabolite that drops most prominently in people taking metformin.
- Citrulline is synthesized from ornithine through a process requiring mitochondrial ATP; inhibited complex I therefore reduces the energy available for intestinal citrulline production.
- The gut-specific NDI1 mice do not show the same fall in blood citrulline, connecting that change to complex I inhibition in the gut.
- Citrulline is taken up by the kidney, converted to arginine, and used to support nitric oxide production and vascular dilation.
- Lower citrulline may reduce vasodilation and nutrient or oxygen delivery during exercise, potentially compromising exercise-induced VO2 max and hypertrophy.
- The available VO2-max evidence comes from short-term studies and does not completely establish the size or persistence of the effect.
- Metformin also lowers vitamin B12 because gut absorption declines, leading to the practical recommendation that people taking it should supplement B12.
- Nav proposes that B12 deficiency raises methylmalonic acid, which may act as a complex I inhibitor and contribute to metformin’s adverse exercise effects.
- Intravenous metformin is taken up primarily by the liver and much less by the gut, whereas a newer delayed-release formulation remains in the gut longer.
- Taking metformin with food can abrogate the postprandial glucose spike through a complex I-dependent mechanism; some studies have linked repeated glucose spikes to all-cause mortality.
- In the ITP, canagliflozin and acarbose extended life when delivered in food, but metformin did not, a discrepancy for which the speaker offers no good explanation.
Why cancer trials fail: metformin must enter the tumor
The strongest proposed explanation for metformin’s disappointing cancer trials is pharmacokinetic rather than a failure of the underlying complex I hypothesis. If tumor cells lack the required transporter, increasing the dose cannot make the drug work.
- Karthik Vasan used CRISPR to knock out individual metabolic genes, producing roughly 3,000 cancer-cell clones.
- About 1,000 clones died, about 1,000 survived, and metformin eliminated all but one of the surviving clones.
- The lone metformin-resistant clone had lost the organic cation transporter needed to cross the plasma membrane, making it insensitive to the drug.
- Three OCT transporters are involved, and they are active, ATP-driven transporters; at least OCT3 is relevant in cancer.
- Blood metformin peaks at only about 10–20 µM, far below gut concentrations.
- Because metformin is cationic and mitochondria maintain a negative charge, metformin at 10 µM is enriched by approximately 100-fold in mitochondria, with published estimates of 100–500-fold accumulation in the matrix.
- The frequency of transporter loss or mutation in tumors matters directly: a high frequency could explain trial failures, while a low frequency would weaken the delivery explanation.
- Human tumor cells could technically be screened for transporter expression and stratified into responsive and nonresponsive groups.
- Most normal tissues, including mammary tissue, likely lack robust transporter expression, making it less likely that a tumor simply acquires the needed transporter by chance.
- The proposed trial design resembles EGFR inhibitors for EGFR-mutant cancers or Herceptin for HER2-positive breast cancer, rather than giving metformin indiscriminately to all patients.
- An alternative biomarker strategy would enroll patients with tumors that are not FDG-positive and then test whether metformin causes new FDG uptake, indicating entry into tumor cells and complex I inhibition.
- The proposed anticancer mechanism is inhibition of the tumor’s TCA-cycle anabolic capacity rather than direct ATP deprivation.
- The possible anti-tumor benefit is not simply reduced proliferation: blocking tumor oxygen consumption could raise local oxygen, improve radiotherapy and immunotherapy, and counteract the hypoxic immunosuppressive tumor microenvironment.
- No cancer patients are currently screened for metformin responsiveness, and no corresponding trials are under way, partly because metformin is inexpensive enough to make organized targeting seem less urgent.
Pollution, mitochondrial signaling, and IL-6
A Northwestern pollution project provides a concrete testable chain from environmental exposure to mitochondrial signaling. The work remains preclinical, and the proposed next step is a human trial rather than a completed clinical result.
- Scott Budinger and Gokhan Mutlu at Northwestern exposed mice to Beijing-level air pollution and found robust increases in IL-6 in both mice and humans.
- IL-6 is prothrombotic and is associated with increased susceptibility to myocardial infarction.
- In alveolar macrophages exposed in vitro to low-dose PM2.5, particulate matter entered mitochondria and increased the H2O2 signal.
- The increased H2O2 signal then drove IL-6 production, establishing a pollution-to-mitochondria-to-H2O2-to-inflammation pathway.
- Metformin added in vitro and in drinking water lowered IL-6 in vivo, work published in Cell Metabolism.
- Metformin in drinking water also reduced pathology in mouse models of SARS-CoV-2 and influenza.
- Alveolar macrophages take up metformin from the blood because they express the necessary OCT transporters.
- The proposed definitive mouse experiment is to restore NDI1 in those macrophages, proving that metformin entered the cells and inhibited complex I rather than acting only through the gut.
- No human intervention data yet show whether metformin reduces pollution-induced inflammation.
- The proposed population experiment would measure CRP for a couple of months; the host proposes testing patients with persistently elevated, unexplained CRP as a more focused clinical design.
Clonal hematopoiesis: the strongest metformin signal
Clonal hematopoiesis of indeterminate potential, or CHIP, is presented as the strongest evidence linking metformin to an age-related mechanism. The association appears in human epidemiology and is supported by mouse experiments that directly test complex I.
- With age, hematopoietic stem cells acquire mutations in epigenetic enzymes and become rogue clones, contributing to inflammation and cardiovascular disease.
- The prevalence of clonal hematopoiesis ranges from approximately 3% to 20%.
- A UK Biobank analysis of about 450,000 people, controlling for diabetes and other factors, found lower incidence of clonal hematopoiesis among metformin users.
- In the same group’s mouse model, metformin reduced clonal hematopoiesis very significantly.
- A reviewer-requested NDI1 experiment showed that metformin binding to complex I prevented mutant clones from outgrowing because the necessary growth building blocks were unavailable.
- The in vitro metformin concentration was 50 µM, a level the speaker called shocking, and the experiment used mouse cells rather than human cells.
- Three papers published simultaneously reached the same overall conclusion: inhibiting the electron transport chain can prevent clonal hematopoiesis.
- Two of those papers appeared in Nature and one in Nature Communications, and the speakers identify metformin as the best safe drug currently available for this pathway.
- Lowering CHIP has been shown in human cells and correlated with metformin use in UK Biobank, but it has never been proactively tested as a clinical endpoint in humans.
- The estimate for a definitive human trial is approximately five years.
Practical metformin guidance and a mechanism-based trial redesign
The discussion separates metformin’s plausible benefits and common adverse effects from the more speculative anti-aging claims. For future research, it argues that trials should measure the pathways metformin is expected to affect rather than treating clinical outcomes as the only endpoints.
- Metformin reliably lowers glucose, and Peter’s practical advice is that taking it before a meal helps keep glucose down.
- Its strongest additional candidate benefit is low-grade anti-inflammatory activity, including the reduction of age-related clonal hematopoiesis.
- The most actionable safety issue is B12 deficiency, which can be addressed with supplementation.
- Nausea is another common problem because it can cause otherwise willing patients to stop treatment.
- When asked about combining metformin with GLP-1 agonists, the speakers report having found no informed answer, even though many patients use both.
- Proposed metformin trials should include continuous glucose monitors over one year, along with CRP and clonal hematopoiesis measurements, so that absorption, metabolic action, and downstream pathways can be tracked.
- The status of the TAME trial is unknown to the speakers.
- A framed atherosclerosis research question asks why some patients still progress despite well-controlled blood pressure and lipids and how much residual risk is attributable to clonal hematopoiesis.
- That question could be tested by identifying patients with excess CHIP and randomizing them to metformin versus no metformin while following both CHIP and cardiovascular outcomes.
- No routine cancer screening for metformin responsiveness exists, even though transporter-based or FDG-PET stratification could identify a more biologically appropriate trial population.
The Warburg effect and the limits of metabolic testing
The speakers challenge both the idea that cancer is fundamentally a mitochondrial disease and the commercial market for blood-based mitochondrial assessments. Their concern is that steady metabolite levels and ratios are routinely mistaken for measurements of metabolic flux.
- The biochemist doubts that human heart failure is caused by intrinsic mitochondrial dysfunction; mouse models of mitochondrial failure do not necessarily translate to human disease, and human evidence is mixed.
- SGLT2 inhibitors work in the kidney by excreting glucose in urine—described as “sweet pee”—and can globally reprogram metabolism, perhaps modestly increasing ketones or fatty acids.
- Their ability to restore heart function is offered as evidence against a simple explanation built on preexisting intrinsic mitochondrial defects.
- No known blood, breath, or other noninvasive test reproducibly measures mitochondrial function.
- Commercial tests measure or infer function from intermediates such as arginine, citrulline, alpha-ketoglutarate, and carnitine, then rely on their levels and ratios.
- The experts call this approach invalid because steady-state concentrations do not reveal flux; a high level can indicate rapid turnover, abundant supply, or a bottleneck upstream.
- Otto Warburg observed in the 1920s that cancer tissue produced much more lactate than normal tissue despite ample oxygen and proposed “injury to respiration” as a prerequisite for cancer.
- Warburg later received a Nobel Prize for work on cytochrome oxidase, the same enzyme that was the subject of the biochemist’s doctoral research.
- Approximately 95–98% of cancers retain a very intact electron transport chain and TCA cycle, using them to generate both ATP and anabolic precursors.
- Only a small number of outliers have TCA or ETC mutations and scavenge macromolecules from the blood.
- Peter agrees that the Warburg effect is real but argues that its usual causal interpretation is wrong: a reproducing, growing cell needs building blocks, and it may use mitochondria more, not less.
- Peter warns that the internet misreads a famous 2009 Science paper with Matthew, Lou, and Craig as declaring cancer a mitochondrial disease curable with supplements, which he characterizes as complete nonsense.
Urolithin A and alpha-ketoglutarate
Urolithin A has a plausible mitophagy mechanism and limited human data, but its pharmacology and lack of a broad clinical effect keep it in a niche. Alpha-ketoglutarate has many known targets and promising disease-specific findings, although its age-related decline may not make supplementation rate limiting.
- Urolithin A undergoes first-pass uptake in the gut and second-pass metabolism in the liver.
- The liver glucuronidates urolithin, leaving free urolithin in plasma at picogram levels while the glucuronide conjugate appears approximately five- to ten-fold higher.
- The conjugate cannot enter cells without deconjugation by enzymes near immune cells, in areas of muscle repair, and in tumors, a process the expert says is not fully understood.
- Direct effects in the gut are an alternative explanation if urolithin never reaches systemic cells in an active form.
- Its proposed mechanism is promotion of mitophagy, the removal of damaged mitochondria.
- One experiment showed that urolithin A made T cells more effective against tumors, while knocking out the mitophagy gene abolished the benefit.
- A human study found slightly less CD8 T-cell exhaustion and reduced inflammation, with plasma containing mainly sugar-conjugated urolithin.
- Compared with metformin’s established glucose-lowering and other effects, urolithin A’s anti-tumor promise is considered niche rather than grounds for routine use.
- A proposed specialized application is a trial during the roughly two-month window surrounding CAR-T therapy, where improved anti-tumor immunity could be tested.
- Alpha-ketoglutarate has roughly 75 known targets and keeps demethylase enzymes active, reducing inappropriate DNA methylation rather than adding methyl groups.
- Maximal demethylase activity is thought to require concentrations around 100 µM, but abundant alpha-ketoglutarate is present and only declines with age, so it is unclear whether supplementation is ever rate limiting.
- A study from Brian Kennedy’s group found that female mice performed better than males, with human trials being established to determine dosing.
- Another group found that genetically increased or supplemented alpha-ketoglutarate promoted intestinal stem cells to become more secretory rather than absorptive, helping against colitis and 5-fluorouracil toxicity.
- Testing a compound for a specific indication such as gut health during chemotherapy requires the IND drug pathway, including a defined indication, claim, and testable hypothesis, rather than the looser supplement pathway.
Carnitine, CoQ10, NAD precursors, and SS31
The broader supplement review applies the same questions to each product: where it goes, what it targets, and whether human evidence supports the claim. Most broad anti-aging promises perform poorly under that framework, although narrower indications remain plausible.
- Carnitine transports fatty acids into mitochondria, but it is probably sufficient even for people who do not eat meat, leaving little evidence that supplementation improves mitochondrial function.
- Statins can affect the CoQ pathway upstream and may lower CoQ enough to become rate limiting in some circumstances.
- CoQ10 trials have failed, partly because of poor bioavailability, and most people already have adequate CoQ.
- For NR and NMN, a recent New York Times article featured experts who disclosed no related commercial interest and indicated that normal age-related NAD decline does not reach rate-limiting levels.
- The resulting answer for general NAD supplementation is largely negative rather than a general anti-aging recommendation.
- A well-executed study from Joe Bower at the University of Pennsylvania did show that NAD supplements can enhance liver regeneration.
- That finding suggests a narrow role in post-surgical recovery or transplantation rather than general geroprotection.
- SS31 is an FDA-approved drug for Barth syndrome, a genetic condition involving low cardiolipin, a mitochondrial membrane component required by cytochrome c oxidase.
- SS31 showed only a weak effect in that extremely rare disease but is marketed to the general public as a mitochondrial booster.
- The trial’s cardiolipin-depleted context may explain the limited effect, because cardiolipin is presumably not rate limiting in most people.
- SS31 could still be repurposed for patients who genuinely have cardiolipin deficiency, despite the mismatch between its approved indication and broader marketing.
Methylene blue, hyperbaric oxygen, and hypoxia
These oxygen-related interventions are judged by their actual physiology and clinical evidence rather than by the novelty of their mechanisms. Most are restricted to narrow indications, and several popular claims are rejected outright.
- Methylene blue takes electrons from NADH at complex I and passes them to complex IV, bypassing complex II and reducing the electrons available to generate superoxide and H2O2.
- It can inhibit monoamine oxidase, which detoxifies dopamine and serotonin, so excessive dosing risks serotonin toxicity and leaves a very narrow therapeutic window.
- The interaction between methylene blue, cytochrome oxidase, and mitochondrial electron shuttles has not been adequately studied, and clinical trials have not resolved those questions.
- Hyperbaric oxygen should not be used except for wound healing, according to the speakers.
- Typical sessions last about 60 minutes and are unlikely to cause acute cell death, but repeated exposure may induce senescence in lung epithelial cells.
- Mouse experiments show that prolonged high oxygen causes senescence and cell death in lung epithelial cells without a corresponding lung benefit.
- There are no dedicated receptors for high oxygen; hyperoxia is proposed to act indirectly by generating free radicals that destabilize the respiratory chain.
- Mice engineered to overexpress an antioxidant protein survived hyperoxia when the apoptosis pathway was disengaged, supporting an indirect oxidative-stress mechanism.
- Popular belief in hyperbaric oxygen’s anti-aging effects partly derives from an Israeli study reporting telomere lengthening, but that study has major methodological holes.
- Low-oxygen therapy appears beneficial for athletes, but there is no stated reason for a healthy person to use it routinely.
- Elderly people can develop pulmonary edema at altitude, a phenomenon studied in the speaker’s laboratory, which makes unsupervised hypoxia particularly risky for them.
- Hypoxia may still have controlled applications as an adjunct to chemotherapy or radiation.
- Hypoxia activates the HIF prolyl hydroxylase/VHL pathway, for which Greg Semenza, Peter Ratcliffe, and William Kaelin received the 2019 Nobel Prize.
- HIF signaling increases erythropoietin, hematocrit, and ventilation, while pulmonary vasoconstriction is HIF-independent and may depend on mitochondria as the oxygen sensor.
Red light therapy
Red light has the strongest clinical support among the speculative mitochondrial interventions for skin applications, but its systemic metabolic mechanism remains unsettled. The speakers separate established skin benefits from an unproven cytochrome oxidase explanation.
- The proposed mechanism is that red light releases nitric oxide from cytochrome oxidase, making the enzyme more efficient, although the speaker does not know whether this occurs in vivo.
- Clinical trials have definitively shown benefit for skin rejuvenation.
- Prior work by the speaker found that small amounts of H2O2 in skin epithelial cells promoted cellular differentiation.
- In one oral glucose-tolerance study, exposing a subject’s back to red light reduced the area under the glucose curve.
- The glucose effect was smaller than that of exercise but larger than placebo.
- One proposed explanation is that cytochrome oxidase inhibition forces glucose uptake in a manner analogous to gut metformin, although lactate should rise if increased glycolysis were the mechanism.
- A formal experiment would engineer mice with a cytochrome oxidase homolog that cannot respond to red light, allowing the cytochrome oxidase mechanism to be tested directly.
- An alternative oxidase from C. elegans can override complex I inhibition, and NDI1 was used as another way to manipulate the pathway for testing.
Funding metabolism as a moonshot
The episode closes with a structural argument about why mitochondrial and metabolic biology remains underfunded relative to its potential. The proposed solution combines public, private, and philanthropic funding around a shared research mission.
- No government, foundation, or philanthropic moonshot for metabolism has ever been attempted, unlike the Human Genome Project.
- Metabolism research has been underfunded for roughly 40 years and was eclipsed by the genomic revolution’s promise that sequencing the human genome would reveal disease within 30 years.
- Gene therapy works well for monogenic diseases, but most other diseases are idiopathic, polygenic, or otherwise unresolved.
- The “golden generation” of metabolism scientists represented by researchers such as Krebs has passed away, and the speaker fears the next generation will leave the field.
- A metabolism moonshot would combine government funding for basic science, biotech development of instruments and drugs, and philanthropy to fill gaps, modeled on the organization of genomic research.
- The speakers argue that biomedical research funding should be doubled or tripled because a less healthy population could bankrupt the country through health-care costs over the next 10 years.
- More money for academia should come with a changed business model rather than simply more of the same funding structure.
- Four National Academy members, including a former Princeton and NIH director and a Nobel laureate, published a PNAS white paper about 12 years earlier on rescuing the biomedical research enterprise, but little came of it.
- The white paper identified insufficient risk-taking, university costs intruding on government grants, and the need for researchers to have more skin in the game rather than operate through a revolving business model.
- US biomedical research has become overly centralized and “imperial,” whereas organizations such as Google operate decentralized independent divisions.
- Universities are also criticized for routing decisions through deans or presidents rather than allowing divisions of biochemistry, medicine, and specialized centers to operate with greater autonomy.
A framework for evaluating drugs and supplements
The episode ends with a compact decision framework that can be applied to any oral intervention. It shifts the question from whether a product sounds biologically plausible to whether exposure, mechanism, and human efficacy line up.
- The first question is where the intervention goes and whether it accumulates everywhere or only in selected tissues.
- The second is what its specific molecular target is.
- The third is whether the intervention works in humans rather than only in mice or isolated laboratory systems.
- Metformin passes the framework more convincingly because its tissue distribution, transporter dependence, complex I target, and human metabolic effects are increasingly well characterized.
- Most broad mitochondrial supplements fail because their tissue distribution, rate-limiting target, and human efficacy remain uncertain.
- The most actionable general measures discussed are maintaining a high VO2 max, using lactate threshold as a practical readout of aerobic and mitochondrial capacity, and supplementing B12 when taking metformin.
- The major unresolved biological questions are how mitochondrial DNA and RNA escape, whether a small leak over 20–30 years causes inflammaging, and whether declining alpha-ketoglutarate impairs methylation and differentiation during ordinary aging.
![[@PeterAttiaMD] Summarizer](https://summaries.pages.dev/img/logo.webp)
